Cigna-Express Scripts deal has already cost $201M

Amy Baxter | | Health Exec | Policy & Regulations
Money

The $67 billion mega-merger between Cigna and Express Scripts has already cost a staggering $201 million, Axios reported.

The deal, which has already been approved by shareholders and cleared by nearly half of the necessary regulators, is anticipated to close in the second half of 2018. Cigna cited the estimated actual transaction costs incurred by the deal in 2018 at $201 million in a filing with the Securities and Exchange Commission (SEC).

The transaction costs will likely be passed onto consumers, Axios reported. The deal brings together a major insurance provider and a large pharmacy benefits manager (PBM) at a time when the healthcare industry is seeing rapid consolidation. Another large PBM, CVS Health, is attempting to acquire insurance provider Aetna for $69 billion.

See the full report below:

The merger tab for Cigna and Express Scripts

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.